Review of ibandronate in the treatment of osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 3, 2003, Pages 391-396

  Chapurlat, Roland D ^a   Delmas, Pierre D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bisphosphonates; Fracture; Ibandronate; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; COLLAGEN TYPE 1; ESTROGEN; IBANDRONIC ACID; INCADRONIC ACID; NITROGEN; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BIOMECHANICS; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; ESTROGEN THERAPY; FEVER; FLATULENCE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HEARTBURN; HUMAN; HYPOCALCEMIA; NAUSEA AND VOMITING; NONHUMAN; OSTEOLYSIS; PHARMACODYNAMICS; POSTMENOPAUSE OSTEOPOROSIS; PROTEINURIA; RANDOMIZATION; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIPHOSPHONATES; HUMANS; INJECTIONS, INTRAVENOUS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037350446     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.3.391     Document Type: Review

References (25)

1. CRANNEY A, WELLS G, WILLAN A et al.: Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. (2002) 23:508-516.
2. CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23:517-523.
3. CRANNEY A, TUGWELL P, ZYTARUK N et al.: Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23:524-528.
4. REID IR, BROWN JP, BURKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2002) 346:653-661.
5. NEER RM, ARNAUD C, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434-1441.
6. MEUNIER PJ, ROUX C, ORTOLANI S et al.: Strontium ranelate reduces the vertebral risk in women with postmenopausal osteoporosis. Osteoporos. Int. (2002) 13(Suppl. 1):O45.
7. MUHLBAUER RC, BAUSS F, SCHENK R et al.: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. (1991) 6:1003-1011.
8. 45Ca kinetics in the intact rat. Osteoporos. Int. (1996) 6:166-170.
9. MONIER-FAUGERE MC, FRIEDLER RM, BAUSS F et al.: A new bisphospohnate, BM-21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J. Bone Miner. Res. (1993) 11:1345-1355.
10. MONIER-FAUGERE MC, GENG Z, PASCHALIS EP et al.: Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effect on bone morphometry and mineral properties. J. Bone Miner. Res. (1999) 14:1768-1778.
11. LALLA S, HOTHORN LA, HAAG N, BADER R, BAUSS F: Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos. Int. (1998) 8:97-103.
12. BAUSS F, WAGNER M, HOTHORN LH: Total administered dose of ibandronate determines effects on bone mass and architecture in ovariectomized aged rats. J. Rheumatol. (2002) 29:990-998.
13. THIEBAUD D, HUSL B, JACQUET AF et al.: Effects of ibandronate IV bolus injection in healthy men and postmenopausal women. J. Bone Miner. Res. (1997) 12(Suppl. 1):S343.
14. RAVN P, CLEMMESEN B, RIIS BJ, CHRISTIANSEN C: The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomised, double-blind, placebo-controlled dose-finding study. Bone (1996) 19:527-533
15. SATO M, GRASSER W, ENDO N et al.: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. (1991) 88:2095-2105.
16. HUGUES DE, WRIGHT KR, UY HL et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. (1995) 10:1478-1487.
17. DUNFORD JE, THOMPSON K, COXON FP et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphophonates. J. Pharmacol. Exp. Ther. (2001) 296:235-242.
18. DOOLEY M, BALFOUR JA: Ibandronate. Drugs (1999) 57:101-108.
19. RAVN P, NEUGEBAUER G, CHRISTIANSEN C: Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone (2002) 30:320-324.
20. THIEBAUD D, BURKHARD TP, KRIEGBAUM H et al.: Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Med. (1997) 103:298-307.
21. RECKER RR, STAKKESTAD JA, FELSENBERG D et al.: a new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis: results of 3-year trial. Osteoporos. Int. (2000) 11(Suppl. 2):S209.
22. RIIS BJ, ISE J, VON STEIN T, BAGGER Y, CHRISTIANSEN C: Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J. Bone Miner. Res. (2001) 16:1871-1878.
23. DELMAS PD, RECKER RR, STAKKESTAD JA et al.: Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal Phase III study. Osteoporos. Int. (2002) 17(Suppl. 1):S15.
24. ADAMI S, DELMAS P, FELSENBERG D et al.: Three monthly 23 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos. Int. (2002) 17(Suppl. 1):S14.
25. PECHERSTORFER M, LUDWIG H, SCHLOSSER K et al.: Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J. Bone Miner. Res. (1996) 11:587-593.